Smoking reduction and tobacco-related cancers: the more things change, the more they stay the same.
Leischow
Scott J
SJ
Djordjevic
Mirjana V
MV
D014408:Biomarkers, Tumor / Q000032:analysis; D002273:Carcinogens / Q000009:adverse effects / Q000032:analysis; D014943:Global Health; D006801:Humans; D007390:International Agencies; D008175:Lung Neoplasms / Q000209:etiology / Q000517:prevention & control; D009369:Neoplasms / Q000453:epidemiology / Q000209:etiology* / Q000517:prevention & control*; D009538:Nicotine / Q000008:administration & dosage*; D018722:Nicotinic Agonists / Q000008:administration & dosage*; D009602:Nitrosamines / Q000009:adverse effects / Q000032:analysis; D012307:Risk Factors; D012907:Smoking / Q000009:adverse effects; D016540:Smoking Cessation / Q000379:methods; D014028:Tobacco Smoke Pollution / Q000009:adverse effects; D014029:Tobacco Use Disorder / Q000150:complications* / Q000453:epidemiology / Q000628:therapy; D014481:United States / Q000453:epidemiology
D014408:Biomarkers, Tumor; D002273:Carcinogens; D018722:Nicotinic Agonists; D009602:Nitrosamines; D014028:Tobacco Smoke Pollution; D009538:Nicotine; C016583:4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone